Table 1 Clinicopathological features of 79 bladder cancer patients and the expressions of circLIFR
From: CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
Parameters | Group | Cases | circLIFR expression | P value | |
|---|---|---|---|---|---|
High | Low | ||||
Gender | Male | 66 | 34 | 32 | 0.7695 |
Female | 13 | 6 | 7 | ||
Age at surgery | < 55 | 11 | 5 | 6 | 0.7555 |
≥55 | 68 | 35 | 33 | ||
Pathological stage | pTa-T1 | 21 | 16 | 5 | 0.0100 |
pT2-T4 | 58 | 24 | 34 | ||
Lymph node metastasis | Absent | 69 | 37 | 32 | 0.1927 |
Present | 10 | 3 | 7 | ||
Vascular invasion | Absent | 72 | 36 | 36 | > 0.9999 |
Present | 7 | 4 | 3 | ||
Muscle invasion | NMIBC | 31 | 21 | 10 | 0.0210 |
MIBC | 48 | 19 | 29 | ||
Total | 79 | 40 | 39 | ||